Skingevity Launches as New UK Medical Aesthetics Group with Three Clinic Acquisitions

A new medical aesthetics group, Skingevity, has officially launched in the UK following the acquisition of three established clinics, positioning itself as a governance-led platform designed to support clinical independence while providing operational infrastructure.

Skingevity was founded by Andrea Agnolio, former Principal at The Boston Consulting Group, and Enrico Ghio, former Executive Director at Goldman Sachs. The group states its aim is to partner with leading doctors and clinics that prioritise clinical excellence and patient care, while offering centralised operational support to reduce administrative pressures.

Three Founding Clinics

At launch, Skingevity includes three clinics across England:

• Dr Joney De Souza Skin and Laser Clinic (Marylebone, London), known for its “less is more” philosophy and over 20 years of aesthetic practice.

• MediZen (Sutton Coldfield, Birmingham), founded in 1999 and led by Dr David Eccleston, recognised for its focus on safety, education and clinical standards.

• Cannelle Skin Clinic (Summertown, Oxford), a long-established clinic now led by Dr Mattia Parducci, combining longstanding client relationships with contemporary aesthetic treatments.

Each clinic will continue operating under its existing name, leadership, and clinical approach. According to Skingevity, continuity of care for patients will remain unchanged.

Centralised Support with Local Leadership

Skingevity’s model centres on providing infrastructure, governance, and operational support to its partner clinics. The group’s central operating team works alongside clinics to drive operational efficiency and growth, while allowing practitioners to focus on clinical work and patient care.

The group is backed by private investors and senior executives, with a stated focus on building long-term, sustainable growth within a sector that is experiencing increasing regulation and complexity.

Dr David Eccleston joins Skingevity as Chief Medical Officer. In this role, he will oversee governance frameworks, education initiatives, and professional development standards across the group, while maintaining local clinical autonomy.

A UK-First Strategy with International Ambitions

Headquartered in London, Skingevity describes itself as adopting a UK-first strategy, with longer-term international ambitions. The group has indicated that it is open to discussions with other established clinics and doctors who are seeking structured operational support while retaining clinical leadership.

Co-CEO and Chief Operating Officer Andrea Agnolio commented that the group was created to provide institutional backing to clinics without compromising their identity or independence. Co-CEO and Chief Financial Officer Enrico Ghio added that the focus is on long-term value built on patient trust, medical standards and responsible governance.

As consolidation and professionalisation continue across the medical aesthetics sector, Skingevity represents a new entrant aiming to balance boutique clinical care with the structure of a centrally governed group.

For more information, visit: https://www.skingevity.co.uk